MARTIN (NUVONURO)-HIT TO LEAD CHEMISTRY-ADMET ONLY- MCSP-HEAL

这项研究是NIH帮助结束长期成瘾（HEAL）计划的一部分，旨在加速科学解决方案，以了解疼痛的基础并加强临床疼痛管理。 承包商在执行本任务单项下的工作时，应 提供一个全面的服务设施和工作人员谁将支持药物化学计划在后期击中 至铅（HTL）阶段，以提供体外吸收、分布、代谢、排泄和毒理学 （ADMET）支持表征结构类似物，以确定最佳临床前候选物， 提供储存和运输的复合后勤，以支持捐助者（马丁，NuvoNuro）， 开发一种有效治疗疼痛的新疗法。本药物化学的范围 支持计划（MCSP）任务订单应为性能领域2下的药物化学服务： 药物化学支持，支持NIH支持的临床前药物发现工作， NINDS及其贡献者。

This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management. The Contractor, in performance of work under this task order, shall provide a full-service facility and staff who will support a medicinal chemistry program in the late Hit to Lead (HTL) phase to provide in vitro absorption, distribution, metabolism, excretion and toxicology (ADMET) support to characterize structural analogs to determine best preclinical candidate and to provide compound logistics of storage and shipping to support the Contributor (Martin, NuvoNuro) in developing a novel therapeutic effective in treating pain. The scope of this Medicinal Chemistry Support Program (MCSP) task order shall be medicinal chemistry services under Performance Area 2: Medicinal Chemistry Support, in support of preclinical drug discovery efforts supported by NIH, NINDS and its Contributors.